X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NurOwn (MSC-NTF Cell Therapy) is an autologous, adult stem cell therapy developed based on a differentiation method which reprograms bone marrow-derived mesenchymal stem cells (MSC) into highly specialized, neuron-supporting cells treatment for amyotrophic lateral sclerosis.
Lead Product(s): MSC-NTF Cell Therapy
Therapeutic Area: Neurology Product Name: NurOwn
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
NurOwn (MSC-NTF Cell Therapy) is an autologous, adult stem cell therapy developed based on a differentiation method which reprograms bone marrow-derived mesenchymal stem cells (MSC) into highly specialized, neuron-supporting cells treatment for amyotrophic lateral sclerosis.
Lead Product(s): MSC-NTF Cell Therapy
Therapeutic Area: Neurology Product Name: NurOwn
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
NurOwn (MSC-NTF Cell Therapy) is an autologous, adult stem cell therapy developed based on a differentiation method which reprograms bone marrow-derived mesenchymal stem cells (MSC) into highly specialized, neuron-supporting cells.
Lead Product(s): MSC-NTF Cell Therapy
Therapeutic Area: Neurology Product Name: NurOwn
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
NurOwn (MSC-NTF Cell Therapy) is an autologous, adult stem cell therapy developed based on a differentiation method which reprograms bone marrow-derived mesenchymal stem cells (MSC) into highly specialized, neuron-supporting cells.
Lead Product(s): MSC-NTF Cell Therapy
Therapeutic Area: Neurology Product Name: NurOwn
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
NurOwn is an autologous, adult stem cell therapy developed based on a differentiation method which reprograms bone marrow-derived mesenchymal stem cells (MSC) into highly specialized, neuron-supporting cells.
Lead Product(s): MSC-NTF cells
Therapeutic Area: Neurology Product Name: NurOwn
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
Lead Product(s): MSC-nTF Cells
Therapeutic Area: Neurology Product Name: NurOwn
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
Lead Product(s): MSC-nTF Cells
Therapeutic Area: Neurology Product Name: NurOwn
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
MSC-NTF cells are produced from autologous, bone marrow-derived MSCs that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of NTFs.
Lead Product(s): MSC-NTF Cells
Therapeutic Area: Neurology Product Name: NurOwn
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2022
Details:
Results from Phase 2, demonstrated NurOwn's safety and provided evidence of its efficacy in people with progressive MS. Biomarker analyses confirmed NurOwn (MSC-NTF cells) proposed MOA by showing consistent treatment effects in neuroinflammation and neuroprotection pathways.
Lead Product(s): MSC-NTF Cells
Therapeutic Area: Neurology Product Name: NurOwn
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
NurOwn-derived exosomes (Exo MSC-NTF) are small extracellular vesicles produced from bone-marrow derived mesenchymal stem cells (MSC) induced to secrete high levels of neurotrophic and other protective factors (MSC-NTF).
Lead Product(s): MSC-NTF Cells
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NurOwn
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
